Pharmacologic therapy of mycotic keratitis.
amphotericin B
antifungal drugs
fungal keratitis
intracameral antifungal
intrastromal antifungal
mycotic keratitis
nanoparticle
natamycin
voriconazole
Journal
Survey of ophthalmology
ISSN: 1879-3304
Titre abrégé: Surv Ophthalmol
Pays: United States
ID NLM: 0404551
Informations de publication
Date de publication:
Historique:
received:
26
12
2017
revised:
06
02
2019
accepted:
06
02
2019
pubmed:
25
2
2019
medline:
28
12
2019
entrez:
25
2
2019
Statut:
ppublish
Résumé
Mycotic keratitis continues to be an important cause of corneal blindness, especially in tropical and subtropical countries. The prognosis is poor compared with many other forms of keratitis because of the lack of effective antifungal drugs. The currently available antifungal drugs suffer from multiple drawbacks such as poor ocular penetration, unpredictable bioavailability, and adverse effects associated with systemic medications. Over the last decade, several new drugs and drug-delivery systems have been introduced in an attempt to improve the treatment outcomes. Thorough knowledge of the currently available antifungal drugs, their spectrum of action, and associated adverse effects is essential to deal with cases of mycotic keratitis. We discuss the pharmacologic properties and clinical use of the currently available antifungal drugs.
Identifiants
pubmed: 30797882
pii: S0039-6257(17)30338-7
doi: 10.1016/j.survophthal.2019.02.007
pii:
doi:
Substances chimiques
Antifungal Agents
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
380-400Informations de copyright
Copyright © 2019 Elsevier Inc. All rights reserved.